评估连续生产的3批冻干MVA-BN®疫苗在健康成人中免疫原性与安全性的随机3期试验
这项随机3期试验将1129名健康成人随机分配至3个批次组,间隔4周接种2剂冻干MVA-BN疫苗。结果显示3批疫苗中和抗体GMT比值在0.936至1.115之间,均在预设等效界值内,血清转化率介于99.1%至99.7%,未发现安全性问题。
要点
- 3批冻干MVA-BN疫苗中和抗体GMT比值介于0.936至1.115,均在预设等效界值内。
- 3个批次组血清转化率介于99.1%至99.7%,免疫原性结果一致。
- 未发现安全性问题,未检出炎症性心脏疾病,未报告相关严重不良事件。
核心结论
- 数据表明冻干剂型MVA-BN疫苗具有一致且稳健的免疫原性和安全性结果。
研究设计与样本
- 随机3期试验,共纳入1129名健康成人,随机分配至3个批次组(批次1至3),间隔4周接种2剂疫苗。
主要发现
- 第二剂接种后2周,所有批次组的中和抗体与总抗体几何平均滴度(GMT)均观察到稳健升高,与已发表数据相当。
- 中和抗体GMT的批次组间比值介于0.936至1.115,置信区间均在预设等效界值内;总抗体结果相似。
- 3个批次的血清转化率介于99.1%至99.7%。
- 未发现安全性问题,尤其未检出炎症性心脏疾病;未报告相关严重不良事件。
- 最常见局部征集性不良事件为注射部位疼痛(87.2%)和红斑(73.2%),最常见全身征集性不良事件为肌痛、疲劳和头痛,发生于40.6%至45.5%的受试者,批次组间无有意义差异。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Since vaccination remains the only effective protection against orthopox virus-induced diseases such as smallpox or monkeypox, the strategic use and stockpiling of these vaccines remains of significant public health importance. The approved liquid-frozen formulation of Bavarian Nordic's Modified Vaccinia Ankara (MVA-BN) smallpox vaccine has specific cold-chain requirements, while the freeze-dried (FD) formulation of this vaccine provides more flexibility in terms of storage conditions and shelf life. In this randomized phase 3 trial, the immunogenicity and safety of 3 consecutively manufactured lots of the FD MVA-BN vaccine was evaluated. A total of 1129 healthy adults were randomized to 3 treatment groups (lots 1 to 3) and received 2 vaccinations 4 weeks apart. For both neutralizing and total antibodies, a robust increase of geometric mean titer (GMT) was observed across all lot groups 2 weeks following the second vaccination, comparable to published data. For the primary results, the ratios of the neutralizing antibody GMTs between the lot group pairs ranged from 0.936 to 1.115, with confidence ratios well within the pre-specified margin of equivalence. Results for total antibodies were similar. In addition, seroconversion rates were high across the 3 lots, ranging between 99.1 % and 99.7 %. No safety concerns were identified; particularly, no inflammatory cardiac disorders were detected. The most common local solicited adverse events (AEs) reported across lot groups were injection site pain (87.2%) and erythema (73.2%), while the most common general solicited adverse events were myalgia, fatigue, and headache in 40.6% to 45.5% of all participants, with no meaningful differences among the lot groups. No related serious AEs were reported. In conclusion, the data demonstrate consistent and robust immunogenicity and safety results with a freeze-dried formulation of MVA-BN. Clinical Trial Registry Number: NCT03699124.
引用
- Turner Overton E, Schmidt D, Vidojkovic S, et al. A randomized phase 3 trial to assess the immunogenicity and safety of 3 consecutively produced lots of freeze-dried MVA-BN® vaccine in healthy adults. Vaccine. 2022. PMID: 36460535. doi:10.1016/j.vaccine.2022.10.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。